TRISTEL plc
("Tristel", the "Company", or the
"Group")
Tristel™
ULT case study
Tristel ULT highlighted as novel method
to simplify high-level disinfection for urological
procedures
Tristel plc (AIM: TSTL), the manufacturer of
infection prevention products utilising proprietary chlorine
dioxide technology, welcomes the publication of a white paper
"Simplifying High-Level
Disinfection for Urological Procedures: A Case Study" at the
American Urological Association ("AUA") 2024 conference, the
largest gathering of urologists in the world. In the paper, US
urologist, Dr Matthew Allaway, highlights Tristel™ ULT in a case
study, commenting on the product's ability to enable faster,
simpler endocavitary probe processing for busy urology
practices.
The paper which was released on 4 May 2024,
highlights Tristel™ ULT as an alternative to conventional chemical
soaking and misting products. In June 2023 the Food and Drug
Administration ("FDA") created a new category of Class II medical
device disinfectants titled "foam or gel chemical
sterilant/high-level disinfectant" under which De Novo clearance
for Tristel™ ULT was granted.
As referenced within Dr Allaway's study,
Tristel™ ULT is recognised as a high level disinfectant ("HLD") and
is effective against pathogens ranging from Human papillomavirus
("HPV") type 16 and type 18 to Mycobacterium terrae. Tristel™ ULT
helps to address numerous bottlenecks that can impact workflow in a
busy urology practice. One of the most time-consuming tasks is
reprocessing medical devices between procedures. Chemical soaking
and misting methods of HLD can damage probes and require complex
workflows limiting the number of procedures clinicians can perform
during a typical patient list. As the paper highlights:
"Unlike
conventional germicidal agents, HLD with Tristel ULT does not
require specialized equipment, plumbing, or electricity and can be
performed at the point of use. Its substantially faster
reprocessing time allows for high throughput-more procedures can be
performed in less time compared to conventional disinfection
methods."
Paul Swinney, CEO of Tristel,
commented: "Our commercial partner, Parker
Laboratories Inc., is presenting Tristel™ ULT alongside its range
of ultrasonic gels and probe covers at multiple healthcare
conferences this year. The most notable is the forthcoming American
Prevention of Infection Congress ("APIC") in Texas in June. We
first announced our FDA approval at this same event held in Orlando
last year. In our first 12 months in the United States market,
brand recognition of Tristel™ ULT has grown rapidly, and this case
study will accelerate our progress further."
For
further information please contact:
|
Tristel plc
|
Tel: 01638 721
500
|
|
Paul Swinney, Chief Executive
Officer
|
www.investors.tristel.com
|
|
Liz Dixon, Chief Financial
Officer
|
|
|
|
|
|
Walbrook PR Ltd
|
Tel: 020 7933 8780
or tristel@walbrookpr.com
|
|
Paul McManus
|
Mob: 07980
541 893
|
|
Alice Woodings
|
Mob: 07407 804 654
|
|
|
|
|
Cavendish Capital Markets Ltd
|
Tel: 020 7220
0500
|
|
Geoff Nash / Charlie Beeson
(Corporate Finance)
|
|
|
Sunila de Silva (ECM)
|
|
About Tristel
plc
Tristel plc is a global infection
prevention company focussed on the manufacture and supply of
products using its unique proprietary chlorine dioxide
(ClO2) chemistry. The Company is a market leader
in manual decontamination of medical devices, supplying
hospitals under the Tristel brand, and under the Cache brand
provides products for sporicidal surface disinfection, in a format
which is a sustainable alternative to commonly used pre-wetted
plastic wipes.
Tristel's head office and manufacturing
facility is located in Snailwell, near Cambridge, and operates
globally employing approximately 250 people across 14 subsidiaries
selling into 40 countries.
The Company has been listed on the London Stock
Exchange's AIM market since 2005 (AIM: TSTL).
For more information about Tristel's product
range please visit: https://tristel.com